Effect of Adipokines in Hemodialysis Patients

Completed · Not applicable · Has a placebo group

Conditions studied: End Stage Renal Disease

In brief

This is a double blinded randomized clinical trial of pioglitazone vs. placebo in overweight or obese, diabetic and non-diabetic hemodialysis patients. This study will examine whether pioglitazone modulates adipokine production by adipose tissue in hemodialysis patients and whether these changes result in reduction of inflammation, insulin resistance and oxidative stress and increase in muscle mass. In addition, this study will also examine the associations of adiposity with adipokines and the metabolic milieu in hemodialysis patients to better understand the biology of adipocytes in uremic milieu.

Key facts

Study ID

NCT01301027

Run by

University of Utah

People needed

95

Starts

2008-05-01

Expected to finish

2015-12-01

Last updated by the study team

2016-10-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Overweight (Body Mass Index ≥ 25 kilograms per meter squared (kg/m2))
• Adult (18 years or older)
• Chronic hemodialysis patient
• Diabetic (type 2) or insulin resistant

You may not qualify if…

• <18 years old
• No insulin resistance
• Active liver disease
• Class III or IV New York Heart Association heart failure
• Macular edema or hard exudates near macula on fundoscopy
• Current active malignancy (excluding squamous and basal cell skin cancers)
• Active AIDS
• Chronic lung disease requiring supplemental oxygen therapy
• Enrolled in interventional trials using drugs or devices
• Bone break of long bones, vertebrae, or hips in the past three years

Where it is running

• University of Colorado — Denver, Colorado, United States
• University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.